Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines debt to equity ratioWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
Revolution Medicines's debt to equity ratio is 0.27: total debt of 639.10M USD against shareholders' equity of 2.40B USD.
- Today
- 0.27
- Average, 5 years
- 0.11
- Low, 5 years
- 0.05
- High, 5 years
- 0.29
Debt to equity = total debt ÷ shareholders' equity = 639.10M ÷ 2.40B = 0.27
Debt to equity
Total debt
Shareholders' equity
Total debt over shareholders' equity at each quarter end.
Debt to equity by year and by quarter
| Fiscal year | Period ending | Debt to equity | Total debt | Shareholders' equity |
|---|---|---|---|---|
| Today | 0.27 | 639.10M | 2.40B | |
| FY2025 | 31 Dec 2025 | 0.10 | 158.70M | 1.63B |
| FY2024 | 31 Dec 2024 | 0.06 | 135.84M | 2.27B |
| FY2023 | 31 Dec 2023 | 0.05 | 87.94M | 1.83B |
| FY2022 | 31 Dec 2022 | 0.09 | 64.21M | 685.19M |
| FY2021 | 31 Dec 2021 | 0.11 | 66.63M | 602.57M |
| FY2020 | 31 Dec 2020 | 0.07 | 32.66M | 474.68M |
| FY2019 | 31 Dec 2019 | 0.00 | 0.00 | 152.54M |
| FY2018 | 31 Dec 2018 | 0.00 | 147.00K | 96.66M |
| FY2017 | 31 Dec 2017 | 0.00 | 0.00 | 4.53M |
| Quarter | Period ending | Debt to equity | Total debt | Shareholders' equity |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 0.27 | 639.10M | 2.40B |
| Q2 FY2026 | 30 Jun 2026 | 0.25 | 641.93M | 2.61B |
| Q1 FY2026 | 31 Mar 2026 | 0.29 | 437.27M | 1.50B |
| Q4 FY2025 | 31 Dec 2025 | 0.10 | 158.70M | 1.63B |
| Q3 FY2025 | 30 Sept 2025 | 0.10 | 158.46M | 1.60B |
| Q2 FY2025 | 30 Jun 2025 | 0.07 | 132.79M | 1.87B |
| Q1 FY2025 | 31 Mar 2025 | 0.06 | 134.34M | 2.08B |
| Q4 FY2024 | 31 Dec 2024 | 0.06 | 135.84M | 2.27B |
| Q3 FY2024 | 30 Sept 2024 | 0.06 | 86.71M | 1.57B |
| Q2 FY2024 | 30 Jun 2024 | 0.05 | 87.41M | 1.62B |
| Q1 FY2024 | 31 Mar 2024 | 0.05 | 88.03M | 1.73B |
| Q4 FY2023 | 31 Dec 2023 | 0.05 | 87.94M | 1.83B |
| Q3 FY2023 | 30 Sept 2023 | 0.08 | 62.85M | 837.46M |
| Q2 FY2023 | 30 Jun 2023 | 0.07 | 63.26M | 930.84M |
| Q1 FY2023 | 31 Mar 2023 | 0.07 | 63.60M | 952.22M |
| Q4 FY2022 | 31 Dec 2022 | 0.09 | 64.21M | 685.19M |
| Q3 FY2022 | 30 Sept 2022 | 0.10 | 65.20M | 681.42M |
| Q2 FY2022 | 30 Jun 2022 | 0.13 | 64.95M | 498.84M |
| Q1 FY2022 | 31 Mar 2022 | 0.12 | 65.91M | 550.99M |
| Q4 FY2021 | 31 Dec 2021 | 0.11 | 66.63M | 602.57M |
| Q3 FY2021 | 30 Sept 2021 | 0.05 | 31.79M | 638.20M |
| Q2 FY2021 | 30 Jun 2021 | 0.05 | 32.49M | 685.01M |
| Q1 FY2021 | 31 Mar 2021 | 0.04 | 31.99M | 722.58M |
| Q4 FY2020 | 31 Dec 2020 | 0.07 | 32.66M | 474.68M |
| Q3 FY2020 | 30 Sept 2020 | 0.07 | 33.38M | 505.07M |
| Q2 FY2020 | 30 Jun 2020 | 0.09 | 34.06M | 360.50M |
| Q1 FY2020 | 31 Mar 2020 | 0.03 | 10.84M | 385.32M |
| Q4 FY2019 | 31 Dec 2019 | 0.00 | 0.00 | 152.54M |
| Q3 FY2019 | 30 Sept 2019 | 0.00 | 157.00K | 165.67M |
| Q2 FY2019 | 30 Jun 2019 | — | — | — |
| Q1 FY2019 | 31 Mar 2019 | 0.00 | 0.00 | 96.66M |
| Q4 FY2018 | 31 Dec 2018 | 0.00 | 147.00K | 96.66M |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:Market cap,ROE (return on equity),Current ratio,All ratios
Common questions about Revolution Medicines's debt to equity
Source: Financial Modeling PrepVerified against SEC filings